MirimGene
MirimGENE is a biotechnology company dedicated to developing innovative medicines, particularly in the fields of autoimmune disorders, infectious diseases, and rare diseases. The company focuses on precision medicine and has developed proprietary platforms such as WITheranostics for targeted theranostics. Led by CEO and founder Dr. Mirim Jin, MirimGENE aims to transform cutting-edge science into life-saving medicines, with a strong emphasis on sepsis theranostics, autoimmune disease treatments, and infectious disease solutions.
Industries
Nr. of Employees
small (1-50)
MirimGene
Room S215, 155, Gaetbeol-ro, Yeonsu-gu, Incheon, Republic of Korea
Patents
Composition for treatment or prevention of infectious inflammatory diseases, or composition for immune enhancement, comprising tryptophanyl-tRNA synthetase as an active ingredient
US-11207389-B2
View Details
Composition for treatment or prevention of infectious inflammatory diseases, or composition for immune enhancement, comprising tryptophanyl-tRNA synthetase as an active ingredient
US-11207389-B2
View DetailsProducts
Sepsis theranostic candidate (WARS1-targeted)
A theranostic approach that combines blood-based WARS1 measurement for patient identification and a targeted neutralizing antibody treatment for hypercytokinemic severe sepsis.
Rheumatoid arthritis candidate (pan-therapeutic mechanism)
Therapeutic candidate designed to suppress multiple proinflammatory cytokines, chemokines and immune effector cells for treatment-resistant rheumatoid arthritis.
Atopic dermatitis candidate
Candidate with a novel mechanism intended to treat severe atopic dermatitis unresponsive to current IL-4/IL-13–targeting biologics.
Inflammatory bowel disease candidate
Novel-mechanism therapeutic candidate for inflammatory bowel diseases with potential improved efficacy.
Neutrophil-dominant COPD candidate
Development of a novel drug targeting neutrophil-dominant COPD subtypes where current treatments are inadequate.
Macrophage activation syndrome (MAS) orphan drug candidate
Orphan drug development for MAS, an autoinflammatory syndrome characterized by cytokine storm and high mortality.
Sepsis theranostic candidate (WARS1-targeted)
A theranostic approach that combines blood-based WARS1 measurement for patient identification and a targeted neutralizing antibody treatment for hypercytokinemic severe sepsis.
Rheumatoid arthritis candidate (pan-therapeutic mechanism)
Therapeutic candidate designed to suppress multiple proinflammatory cytokines, chemokines and immune effector cells for treatment-resistant rheumatoid arthritis.
Atopic dermatitis candidate
Candidate with a novel mechanism intended to treat severe atopic dermatitis unresponsive to current IL-4/IL-13–targeting biologics.
Inflammatory bowel disease candidate
Novel-mechanism therapeutic candidate for inflammatory bowel diseases with potential improved efficacy.
Neutrophil-dominant COPD candidate
Development of a novel drug targeting neutrophil-dominant COPD subtypes where current treatments are inadequate.
Macrophage activation syndrome (MAS) orphan drug candidate
Orphan drug development for MAS, an autoinflammatory syndrome characterized by cytokine storm and high mortality.
Services
Collaborative agreements and joint development activities with external pharmaceutical, CDMO and diagnostic partners to advance therapeutic and diagnostic candidates.
Management and execution of government- and grant-funded translational R&D projects and participation in national drug development programs.
Collaborative agreements and joint development activities with external pharmaceutical, CDMO and diagnostic partners to advance therapeutic and diagnostic candidates.
Management and execution of government- and grant-funded translational R&D projects and participation in national drug development programs.
Expertise Areas
- Biomarker discovery and validation
- Theranostics development
- Antibody therapeutic discovery and preclinical development
- Preclinical disease models and in vivo efficacy testing
Key Technologies
- WARS1 (tryptophanyl-tRNA synthetase 1) biomarker analysis
- Neutralizing antibody therapeutics
- Theranostics platforms
- Recombinant protein therapeutics
News & Updates
Professor Mirim Jin delivered a lecture on 'Highly secreted tryptophanyl-tRNA synthetase as a theranostic target for hypercytokinemic severe sepsis' at the 2024 Biomolecular Horizons Congress in Melbourne, Australia.
MirimGENE and PCMO are co-developing a recombinant protein therapy for Tuberculosis based on targeting WARS1, aiming for innovative treatment options.
Dr. Jin received the award for her research published in Biomolecules & Therapeutics on phytochemicals acting on synaptic plasticity as potential prophylaxis against stress-induced depressive disorder.
MirimGENE and BORYUNG are collaborating to develop innovative drugs for resistant autoimmune diseases, aiming to accelerate drug development and industry competitiveness.
Research targeting WARS1 for sepsis theranostics was published in EMBO Molecular Medicine, highlighting the potential to improve survival rates in septic shock.
MirimGENE and BORYUNG signed an MOU to collaborate on developing innovative drugs for resistant autoimmune diseases.
Professor Mirim Jin delivered a lecture on 'Highly secreted tryptophanyl-tRNA synthetase as a theranostic target for hypercytokinemic severe sepsis' at the 2024 Biomolecular Horizons Congress in Melbourne, Australia.
MirimGENE and PCMO are co-developing a recombinant protein therapy for Tuberculosis based on targeting WARS1, aiming for innovative treatment options.
Dr. Jin received the award for her research published in Biomolecules & Therapeutics on phytochemicals acting on synaptic plasticity as potential prophylaxis against stress-induced depressive disorder.
MirimGENE and BORYUNG are collaborating to develop innovative drugs for resistant autoimmune diseases, aiming to accelerate drug development and industry competitiveness.
Research targeting WARS1 for sepsis theranostics was published in EMBO Molecular Medicine, highlighting the potential to improve survival rates in septic shock.
MirimGENE and BORYUNG signed an MOU to collaborate on developing innovative drugs for resistant autoimmune diseases.